The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Early analysis of ODYSSEY: momelotinib plus luspatercept in transfusion-dependent myelofibrosis
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the preliminary results of the ODYSSEY trial (NCT06517875), which evaluates the efficacy and safety of momelotinib in combination with luspatercept in patients with transfusion-dependent myelofibrosis (MF). Dr Bose provides insight into the rationale for combining these two agents and notes that early clinical activity has been observed. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
